Britain and America have hammered out a significant commercial pact that will ensure no levies on British drug exports entering the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on medicines through the NHS. This move ensures that duties on these vital goods will stay at nothing for a period of 36 months.
This agreement comes after recent threats to significantly raise import taxes on branded drug imports, with figures floated as high as double the cost.
"This arrangement between the Britain strengthens the global environment for innovative medicines and establishes much-needed balance to transatlantic pharmaceutical trade," an announcement said.
Trade Impact
Medicines are one of the Britain's largest exports to the America, which is easily the biggest market for major British pharmaceutical firms.
Export figures indicate that in the year prior to September, the UK exported pharmaceutical products worth billions to the US. This value represented 17.4% of all goods exports in that timeframe.
"This guarantee protects employment, increases funding and paves the way for the UK to become a global hub for life sciences," the Business and Trade Secretary remarked.
Key NHS Changes
The agreement involves several key commitments from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to raise overall public funding on treatments from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The sum drug companies must refund to the NHS to stay within budget will be limited at 15%. Previously, repayments were more than twenty percent.
Industry Background
This agreement comes amid a ongoing row between the sector and the UK government over medicine costs and NHS adoption.
The disagreement were intensified by assertions that American patients were charged several times more for the equivalent treatments than patients in the other developed nations.
Recently, several significant drug company projects in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been announced toward US facilities.
The Science Minister stated that the NHS must spend more on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the previous ten-year period.
